Retina transduction by rAAV2 after intravitreal injection: comparison between mouse and rat
The DOI matches its Crossref record; 73 of the 76 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus vectors (rAAV) are currently the most common vehicle used in clinical trials of retinal gene therapy, usually delivered through subretinal injections to target cells of the outer retina. However, targeting the inner retina requires intravitreal injections, a simple and safe procedure, which is effective for transducing the rodent retina, but still of low efficiency in the eyes of primates. We investigated whether adjuvant pharmacological agents may enhance rAAV transduction of the retinas of mouse and rat after intravitreal delivery. Tyrosine kinase inhibitors were highly efficient in mice, especially imatinib and genistein, and promoted transduction even of the outer retina. In rats, however, we report that they were not effective. Even with direct proteasomal inhibition in rats, the effects upon transduction were only minimal and restricted to the inner retina. Even tyrosine capsid mutant rAAVs in rats had a transduction profile similar to wtAAV. Thus, the differences between mouse and rat, in both eye size and the inner limiting membrane, compromise the efficiency of AAV vectors penetration from the vitreous into the retina, and impact the efficacy of strategies developed to enhance intravitreal retinal rAAV transduction. Further improvement of strategies, then are required.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, the application of tyrosine kinase inhibitors might improve the passage of rAAV through the ILM or OLM [307].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [307]
Citations
Cites
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 1×
“Its structural simplicity, lack of pathogenicity, and natural ability to infect both dividing and non-dividing human cells were critical for the development of recombinant AAV-based gene therapy vectors [1].”
BackgroundZolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
(1984) · PubMed · Cited by 1,200
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881 · cited 1×
“The vector’s ability to mediate long-term expression as episomes, without integration into the host DNA, its low immunogenicity, and high production yields are desirable characteristics for therapeutic applications [2].”
BackgroundDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 2×
“overcome ILM barrier is capsid mutation, which may be achieved by rational design or directed evolution, and has potential to alter vector interaction with structural components of the ILM, such heparan sulfate, and enhance penetration into the retina [23, 24, 70].”
BackgroundFisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citation
Research works printed but not linked: 1
- Xiong L, Quan YL, Zheng YP, Zhang LM, Zhang LY, Xiong QC. Effects of platelet-derived growth factor α receptor in experimental rabbit PVR. Int J Ophthalmol. 2009;2:261–5.
Cited by
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“Enzymatic digestion (proteasome inhibitors) of the ILM or ILM/outer limiting membrane (OLM) or disruptions of the ILM/OLM by the disease can alter rAAV infection and allow rAAV infection deeper into the retina [99,294,304,305].”
BackgroundInfluentialThe future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
“In particular, vectors that exhibit high efficacy in mice do not necessarily result in similar efficacy in larger eyes (Boyd et al., 2016a; Ramachandran et al., 2017; Dias et al., 2019; Ross et al., 2020) (Table 2).”
BackgroundInfluentialOcular Barriers and Their Influence on Gene Therapy Products Delivery
Leclercq, B., Mejlachowicz, D., & Béhar‐Cohen, F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050998 · Cited by 62
“Techniques are currently aimed at combining the intravitreal injection of viral vectors after removing the ILM by peeling [69] or with an injection under the ILM [70].”
BackgroundInfluentialRetinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations
Talib, M., & Boon, C. J. F. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000290 · Cited by 41
“Intravitreal gene therapy administration may theoretically provide a better outcome in the peripheral visual function these patients, although it currently holds a higher risk of inflammation and systemic biodistribution, and a lower degree of efficacy than subretinal administration in the eyes of primates.(227) Shoul…”
BackgroundDual-AAV delivery of large gene sequences to the inner ear
Reisinger, E. (2020) · Hearing Research · doi:10.1016/j.heares.2019.107857 · Cited by 37
Metadata
- Authors
- Dias, M. S., Araujo, V. G., Vasconcelos, T., Li, Q., Hauswirth, W. W., Linden, R., & Petrs-Silva, H.
- Affiliations
- Universidade Federal do Rio de Janeiro (BR)
- University of Florida (US)
- Corresponding author
- Dias, Mariana S.
- Venue
- Gene Therapy
- Published
- 2019-09-27
- Volume
- 26
- Issue
- 12
- Pages
- 479-490
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W2977028502
- Cited by
- 17
- References
- 76
- Citations by year
- 2025: 1 · 2022: 7 · 2021: 3 · 2020: 5 · 2019: 1
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Eye Institute (R01EY021752)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, rAAV2, intravitreal injection, retinal transduction, inner retina, tyrosine kinase inhibitors, imatinib, genistein, proteasome inhibition, mouse-rat comparison, internal limiting membrane, retinal gene therapy
- MeSH terms
- Imatinib Mesylate, Dependovirus, Adjuvants, Pharmaceutic, Animals, Electroretinography, Genetic Vectors, Mutation, Retina, Transduction, Genetic, Genetic Therapy, Genistein, Protein Kinase Inhibitors, Mice, Rats, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Retina transduction by rAAV2 after intravitreal injection: comparison between mouse and rat. https://app.cochat.ai/papers/10.1038/s41434-019-0100-9
- The paper
- Dias, M. S., Araujo, V. G., Vasconcelos, T., Li, Q., Hauswirth, W. W., Linden, R., & Petrs-Silva, H. (2019). Retina transduction by rAAV2 after intravitreal injection: comparison between mouse and rat. Gene Therapy. https://doi.org/10.1038/s41434-019-0100-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.